If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Company Timeline (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
178.00    3.00 (1.71%)
Bid:
176.50
Ask:
178.00
Spread: 1.50 (0.85%)
Market Cap: £1.53b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Latest Timeline Updates for Hutchmed

HCM

News
2 Jul 2026 14:26
Hutchmed

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer with "a very poor prognosis".

HCM

News
2 Jul 2026 12:07
Hutchmed

LONDON MARKET MIDDAY: FTSE 100 rises ahead of crucial US jobs report

(Alliance News) - Stock prices in London were mixed at midday on Thursday, as the FTSE 100 outperformed the mid-cap index as investors focused on the upcoming US jobs report for further clues on the F...

HCM

News
2 Jul 2026 11:04
Hutchmed

WINNERS & LOSERS: Capricorn jumps after agreeing to Genel takeover

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

HCM

RNS
2 Jul 2026 09:30
Hutchmed

Date:
02-Jul-26

Time:
9:30 am

Source:
RNS

HCM

RNS
30 Jun 2026 09:30
Hutchmed

Date:
30-Jun-26

Time:
9:30 am

Source:
RNS

HCM

RNS
29 Jun 2026 09:30
Hutchmed

Date:
29-Jun-26

Time:
9:30 am

Source:
RNS

HCM

News
25 Jun 2026 11:25
Hutchmed

Hutchmed China reports positive phase two fanregratinib study data

(Alliance News) - Hutchmed China Ltd on Thursday reported positive phase two data for fanregratinib in patients with intrahepatic cholangiocarcinoma, showing clinically meaningful and durable response...

HCM

RNS
25 Jun 2026 07:00
Hutchmed

Date:
25-Jun-26

Time:
7:00 am

Source:
RNS-R

HCM

News
12 Jun 2026 16:24
Hutchmed

Hutchmed highlights data for sovleplenib in rare blood disorder

(Alliance News) - Hutchmed China Ltd on Friday said phase III trial results for its investigational drug sovleplenib showed significant efficacy and a favourable safety profile in patients with warm a...

HCM

RNS
12 Jun 2026 07:00
Hutchmed

Date:
12-Jun-26

Time:
7:00 am

Source:
RNS-R